Navigation Links
Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
Date:10/20/2010

0%, compared to 4.4% in the prior year. Days sales outstanding were 43 days, unchanged from the beginning of the year. Cash flow from operations was $330 million compared to $374 million for 2009. During the quarter, the company repurchased $324 million of its common shares and made capital expenditures of $47 million.

Year-to-Date PerformanceFor the first nine months of 2010, income from continuing operations was $556 million, or $3.09 per diluted share, compared to $549 million, or $2.91 per diluted share, for the first nine months of 2009. Revenues of $5.5 billion were 1.1% below the prior year level.

Operating income for the first nine months of 2010 was $1.0 billion, or 18.1% of revenues, compared to $1.0 billion, or 18.3% of revenues, for 2009. Cash from operations was $778 million, compared to $637 million in the first nine months of 2009. Cash provided by operations in 2009 was reduced by the net impact of the NID settlement. During the first nine months of 2010, the company repurchased $750 million of its shares and made capital expenditures of $136 million.

Outlook for the Full-Year 2010 UpdatedFull-year 2010 guidance, before potential special items, is:

  • Earnings per diluted share from continuing operations, $3.95 to $4.00;
  • Revenues, approximately 1.5% below the prior year, versus previous expectation of  approximately 1% below the prior year;
  • Operating income, between 17.5% and 18% of revenues;
  • Cash from operations, approximately $1.1 billion; and
  • Capital expenditures, approximately $200 million.

  • Quest Diagnostics will hold its third quarter conference call on October 20, 2010 at 8:30 a.m. Eastern Time. The public may access the conference call through a live audio webcast available on Quest Diagnostics' Investor Relations Internet site at www.QuestDiagnostics.com/investor. The conference call can also be accessed
    '/>"/>

    SOURCE Quest Diagnostics Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
    2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
    3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
    4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
    5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
    6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
    7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
    8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
    9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
    11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... , July 23, 2014 Today,s U.S. ... to treat patients with relapsed chronic lymphocytic leukemia ... (SLL) is a significant advance for patients with ... goes by the trade name Zydelig®, is a ... is highly expressed in many B-cell malignancies and ...
    (Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
    (Date:7/23/2014)... , July 23, 2014 UBM Medica US ... a new online community and information resource for neurologists ... and treat their patients with neurological disorders . ... an aging population, necessitates greater access to dedicated information ... statistics on neurological conditions include: , 1 ...
    Breaking Medicine Technology:The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3
    ... that a new market research report is available in ... Device Market Outlook to 2015 ... manufacturers are experiencing profit margin pressures due to large ... contract prices for the device supplies, and some devices ...
    ... Reportlinker.com announces that a new market research ... The 2011 Clinical Chemistry Market: US, ... During the next decade, ... The changes will be caused by convergence of ...
    Cached Medicine Technology:Reportlinker Adds The Drug Delivery Device Market Outlook to 2015 2Reportlinker Adds The Drug Delivery Device Market Outlook to 2015 3Reportlinker Adds The 2011 Clinical Chemistry Market: US, Europe, Japan 2
    (Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... powerful drug combo may not be as effective against ... human cells suggests that one of the medications might ... study,s findings aren,t definitive, and there,s still hope for ... lumacaftor, according to the study,s senior author. "The ...
    (Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
    (Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
    (Date:7/23/2014)... 23, 2014 The next episode of ... Milwaukee, Wis. who was physically fit through childhood and ... ultimately made the heart-wrenching decision to give her son ... the past 18 years, and she punished herself by ... Featuring a unique, non-competitive approach to weight loss transformations, ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 Celebrating a ... New Jersey today announced the awarding of $1,070,000 in ... special award in recognition of the Foundation’s 1,000th grant. ... to continue our tradition of supporting community-based organizations that ... quality of life in the Garden State,” said Robert ...
    Breaking Medicine News(10 mins):Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5
    ... to provide guidance for global market development.SUNNYVALE, Calif. ... Systems, Inc., a technology leader in developing novel ... of Hironori Yamamoto, MD, PhD, of Jichi Medical ... privileged that Dr. Yamamoto has elected to join ...
    ... Other Health Insurers Are Illegally Denying Treatment to Autistic ... being released by Consumer Watchdog: Who: Guillermo Arce , ... father of Frank Nagle , Harvey Rosenfield ... insurance reform initiative, Proposition 103 , Scott Glovsky ...
    ... how autoimmune diseases are triggered , , TUESDAY, Feb. ... by exposure to pig brains might help researchers learn ... More than a year ago, workers at pork processing ... and tingling in their arms and legs. Their common ...
    ... MDVN ) today announced that it will ... on Wednesday, February 25, at 4:30 p.m. Eastern Time ... ongoing Phase 1-2 clinical trial of the Company,s novel ... Scher, M.D., principal investigator of the trial and chief ...
    ... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the ... facilities, today announced that its Board of Directors has ... the public entity from July 31st to December 31st. ... and re-incorporation was completed and approved on February 16, ...
    ... HARRISBURG, Pa., Feb. 24 Swiss Villa Dairy Farm ... monocytogenes contamination and resumed sales of raw milk on ... milk is milk that has not been pasteurized. ... have samples of their milk laboratory tested due to ...
    Cached Medicine News:Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 2Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 3Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 4Health News:Parents of Autistic Children Fight Back - Warn HMO Regulator Against Changing Rules to Favor Insurers That Deny Access to Medical Treatment 2Health News:Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients 2Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: